EP2301960A3 - Conjugués polymères de neublastine mutée - Google Patents

Conjugués polymères de neublastine mutée Download PDF

Info

Publication number
EP2301960A3
EP2301960A3 EP10181704A EP10181704A EP2301960A3 EP 2301960 A3 EP2301960 A3 EP 2301960A3 EP 10181704 A EP10181704 A EP 10181704A EP 10181704 A EP10181704 A EP 10181704A EP 2301960 A3 EP2301960 A3 EP 2301960A3
Authority
EP
European Patent Office
Prior art keywords
polymer conjugates
mutated neublastin
neublastin
mutated
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10181704A
Other languages
German (de)
English (en)
Other versions
EP2301960A2 (fr
Inventor
Dinah Wen-Yee Sah
R. Blake Pepinsky
Paula Ann Boriack-Sjodin
Stephan S. Miller
Anthony Rossomando
Laura Silvian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen Idec Inc
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/356,264 external-priority patent/US7442370B2/en
Application filed by Biogen Idec Inc, Biogen Idec MA Inc filed Critical Biogen Idec Inc
Publication of EP2301960A2 publication Critical patent/EP2301960A2/fr
Publication of EP2301960A3 publication Critical patent/EP2301960A3/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
EP10181704A 2003-01-31 2004-02-02 Conjugués polymères de neublastine mutée Withdrawn EP2301960A3 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/356,264 US7442370B2 (en) 2001-02-01 2003-01-31 Polymer conjugates of mutated neublastin
EP04707363A EP1594436B1 (fr) 2003-01-31 2004-02-02 Neublastine mutee
EP10173737.7A EP2246362B1 (fr) 2003-01-31 2004-02-02 Conjugués polymères de neublastine mutée

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP04707363.0 Division 2004-02-02
EP10173737.7 Division 2010-08-23

Publications (2)

Publication Number Publication Date
EP2301960A2 EP2301960A2 (fr) 2011-03-30
EP2301960A3 true EP2301960A3 (fr) 2011-08-03

Family

ID=35006489

Family Applications (3)

Application Number Title Priority Date Filing Date
EP04707363A Expired - Lifetime EP1594436B1 (fr) 2003-01-31 2004-02-02 Neublastine mutee
EP10181704A Withdrawn EP2301960A3 (fr) 2003-01-31 2004-02-02 Conjugués polymères de neublastine mutée
EP10173737.7A Expired - Lifetime EP2246362B1 (fr) 2003-01-31 2004-02-02 Conjugués polymères de neublastine mutée

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP04707363A Expired - Lifetime EP1594436B1 (fr) 2003-01-31 2004-02-02 Neublastine mutee

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP10173737.7A Expired - Lifetime EP2246362B1 (fr) 2003-01-31 2004-02-02 Conjugués polymères de neublastine mutée

Country Status (26)

Country Link
EP (3) EP1594436B1 (fr)
JP (3) JP4742025B2 (fr)
KR (2) KR101216331B1 (fr)
CN (2) CN101166753A (fr)
AT (1) ATE478891T1 (fr)
AU (1) AU2004209966B9 (fr)
BR (1) BRPI0407170A (fr)
CA (1) CA2514510C (fr)
CY (2) CY1111196T1 (fr)
DE (1) DE602004028801D1 (fr)
DK (2) DK2246362T3 (fr)
EA (1) EA008743B1 (fr)
ES (2) ES2351215T3 (fr)
GE (3) GEP20135982B (fr)
IL (2) IL169945A (fr)
IS (1) IS7938A (fr)
ME (1) MEP43808A (fr)
MX (1) MXPA05008168A (fr)
NO (1) NO20054025L (fr)
NZ (2) NZ541921A (fr)
PL (1) PL383683A1 (fr)
PT (2) PT2246362E (fr)
RS (1) RS52910B (fr)
SI (2) SI2246362T1 (fr)
UA (2) UA105892C2 (fr)
ZA (1) ZA200505707B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004028801D1 (de) * 2003-01-31 2010-10-07 Biogen Idec Inc Neublastin-mutanten
KR101241551B1 (ko) * 2004-08-19 2013-03-11 바이오겐 아이덱 엠에이 인코포레이티드 전환 성장 인자 베타 패밀리 단백질의 리폴딩
US20140092376A1 (en) * 2012-10-01 2014-04-03 Momentive Performance Materials, Inc. Container and method for in-line analysis of protein compositions
SG11201906552WA (en) * 2017-01-25 2019-08-27 Tessa Therapeutics Pte Ltd TGF-ß DECOY RECEPTOR
US20230074641A1 (en) * 2020-01-27 2023-03-09 Silcotek Corp. Biopharmaceutical manufacturing process and product

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020055467A1 (en) * 1998-07-06 2002-05-09 Johansen Teit E. Novel neurotrophic factors
WO2002060929A2 (fr) * 2001-02-01 2002-08-08 Biogen, Inc. Conjugues polymeres de neublastine et methodes d'utilisation a
WO2002078730A2 (fr) * 2001-03-28 2002-10-10 Biogen, Inc. Traitement utilisant des polypeptides de neublastine
WO2004094592A2 (fr) * 2003-04-18 2004-11-04 Biogen Idec Ma Inc. Neublastine a conjugaison polymere glycosylee

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU187037B (en) 1983-04-19 1985-10-28 Tibor Sinko Rope-stretching device
EP0154316B1 (fr) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Lymphokine chimiquement modifiée et son procédé de préparation
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
EP0606217B2 (fr) 1991-06-27 2008-12-03 Bristol-Myers Squibb Company Recepteur ctl4a proteines de fusion contenant ce recepteur et utilisations correspondantes
CA2092271C (fr) 1993-03-09 2009-10-13 Eddie Reed Utilisation de fsc-g pour traiter les effets secondaires du taxol
US5834029A (en) 1994-07-20 1998-11-10 Cytotherapeutics, Inc. Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
DE69736428T2 (de) 1996-05-08 2007-08-30 Biogen Idec Ma Inc., Cambridge RET-LIGAND 3 (RetL3), UM NEURALES UND RENALES WACHSTUM ZU STIMULIEREN
KR100195886B1 (ko) 1996-11-01 1999-06-15 김상조 당뇨병 치료용 의약조성물
CN1269805A (zh) * 1997-07-14 2000-10-11 博尔德生物技术公司 生长激素和相关蛋白的衍生物
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
US20020002269A1 (en) * 1998-09-29 2002-01-03 Jeffrey D. Milbrandt Artemin, a neurotrophic factor
WO2000034475A2 (fr) * 1998-12-09 2000-06-15 Amgen Inc. Facteur de croissance neurotrophique issu des cellules gliales (grnf4), un facteur neurotrophique
IL156559A0 (en) * 2000-12-22 2004-01-04 Genentech Inc New use of artemin, a member of the gdnf ligand family
DE602004028801D1 (de) * 2003-01-31 2010-10-07 Biogen Idec Inc Neublastin-mutanten

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020055467A1 (en) * 1998-07-06 2002-05-09 Johansen Teit E. Novel neurotrophic factors
WO2002060929A2 (fr) * 2001-02-01 2002-08-08 Biogen, Inc. Conjugues polymeres de neublastine et methodes d'utilisation a
WO2002072826A2 (fr) * 2001-03-12 2002-09-19 Biogen, Inc. Nouveaux facteurs neurotrophiques
WO2002078730A2 (fr) * 2001-03-28 2002-10-10 Biogen, Inc. Traitement utilisant des polypeptides de neublastine
WO2004094592A2 (fr) * 2003-04-18 2004-11-04 Biogen Idec Ma Inc. Neublastine a conjugaison polymere glycosylee

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROSSOMANDO A J ET AL: "IN VITRO AND IN VIVO CHARACTERIZATION OF NEUBLASTIN, A NOCICEPTIVE NEURONAL TROPHIC FACTOR", ABSTRACTS OF THE ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE, SOCIETY FOR NEUROSCIENCE, WASHINGTON, DC, US, vol. 27, no. 1, 1 January 2001 (2001-01-01), pages 361, XP001121851, ISSN: 0190-5295 *

Also Published As

Publication number Publication date
JP2010184924A (ja) 2010-08-26
EA200501212A2 (ru) 2006-08-25
SI1594436T1 (sl) 2011-01-31
HK1085663A1 (en) 2006-09-01
EP2246362B1 (fr) 2013-12-18
ES2351215T3 (es) 2011-02-01
CN102367277B (zh) 2014-04-09
EP2246362A3 (fr) 2011-02-23
MEP43808A (en) 2011-02-10
GEP20084464B (en) 2008-08-25
EA200501212A3 (ru) 2006-10-27
IS7938A (is) 2005-07-12
DE602004028801D1 (de) 2010-10-07
NO20054025L (no) 2005-10-31
KR101293805B1 (ko) 2013-08-06
EP1594436A2 (fr) 2005-11-16
MXPA05008168A (es) 2005-10-05
NZ581460A (en) 2010-02-26
JP2011078434A (ja) 2011-04-21
IL227752A0 (en) 2013-09-30
EP1594436A4 (fr) 2008-05-28
JP4742025B2 (ja) 2011-08-10
PL383683A1 (pl) 2008-04-14
ES2450115T3 (es) 2014-03-24
EP1594436B1 (fr) 2010-08-25
KR101216331B1 (ko) 2012-12-28
SI2246362T1 (sl) 2014-04-30
KR20050099514A (ko) 2005-10-13
AU2004209966A2 (en) 2004-08-19
ZA200505707B (en) 2007-01-31
CA2514510C (fr) 2013-10-01
UA105892C2 (uk) 2014-07-10
GEP20135982B (en) 2013-12-10
EA008743B1 (ru) 2007-08-31
EP2301960A2 (fr) 2011-03-30
JP2007525152A (ja) 2007-09-06
PT1594436E (pt) 2010-11-29
CN101166753A (zh) 2008-04-23
RS52910B (sr) 2014-02-28
CY1115085T1 (el) 2016-12-14
CA2514510A1 (fr) 2004-08-19
DK2246362T3 (en) 2014-03-10
AU2004209966B9 (en) 2008-06-26
CN102367277A (zh) 2012-03-07
AU2004209966A1 (en) 2004-08-19
IL169945A (en) 2015-03-31
AU2004209966B2 (en) 2008-04-17
GEP20115137B (en) 2011-01-10
RS20050585A (sr) 2007-11-15
ATE478891T1 (de) 2010-09-15
BRPI0407170A (pt) 2006-02-21
KR20120099161A (ko) 2012-09-06
NO20054025D0 (no) 2005-08-30
PT2246362E (pt) 2014-03-10
UA91178C2 (ru) 2010-07-12
DK1594436T3 (da) 2010-12-13
EP2246362A2 (fr) 2010-11-03
CY1111196T1 (el) 2015-06-11
NZ541921A (en) 2010-01-29

Similar Documents

Publication Publication Date Title
WO2004069176A3 (fr) Conjugues polymeres de neublastine mutee
USD454705S1 (en) Chair to facilitate pedicures and other care of the feet
CA2283939A1 (fr) Conjugues de polymeres ramifies non antigeniques
AU2002365360A1 (en) Biologically active non-antigenic copolymer and conjugates thereof and methods for producing the same
WO2004091517A3 (fr) Conjugues comprenant l'interleukine 18 humaine il 18 et mutants de ces conjugues par substitution
IL227752A0 (en) Polymer conjugates of modified neoblastin
CY1106886T1 (el) Πολυμερη προϊοντα συζευξης της neublastin και μεθοδοι χρησης αυτων
AU2575000A (en) Collagen-binding physiologically active polypeptide
AU2002364044A1 (en) Ultrasound sensing of concentration of methanol's aqueous solution
EP1618179A4 (fr) Neublastine a conjugaison polymere glycosylee
USD440680S1 (en) Hamburger lamp
USD469676S1 (en) Basting tack cutter
EP1403279A4 (fr) Polymere proteique presentant une activite de depliage sur la structure proteique d'ordre superieur
AU2003298570A1 (en) Isolated human hepsin/46 proteins, nucleic acid molecules encoding human hepsin/46 proteins, and uses thereof
FR2773713B1 (fr) Composition alimentaire ou medicamenteuse a base de fer particulierement assimilable par l'organisme humain et preparations adaptees
AUPR483101A0 (en) Animal feed and compositon's and its use in raise of vitamin A,D & E in milk
AU4823901A (en) A novel polypeptide, glucose transport-associated human protein 10 and the polynucleotide encoding the polypeptide
AU2002235434A1 (en) 15569, a novel human g protein coupled receptor and uses therefor
HK1088823A (en) Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
AU1198701A (en) Novel human membrane proteins
AU2002336916A1 (en) Dicarboxylic acid derivatives, their preparation and therapeutical use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 2246362

Country of ref document: EP

Kind code of ref document: P

Ref document number: 1594436

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/475 20060101AFI20110629BHEP

Ipc: A61K 47/48 20060101ALI20110629BHEP

17P Request for examination filed

Effective date: 20120201

17Q First examination report despatched

Effective date: 20120224

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1156051

Country of ref document: HK

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20140207

INTG Intention to grant announced

Effective date: 20140220

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIOGEN MA INC.

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20151015

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160226

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1156051

Country of ref document: HK